Brief: Odonate Therapeutics Q4 Loss Per Share $1.17

Odonate

22/02/2019 13:28

Feb 22 (Reuters) - Odonate Therapeutics Inc  ODT.O :
    * ODONATE THERAPEUTICS ANNOUNCES FINANCIAL RESULTS FOR THE
THREE
AND TWELVE MONTHS ENDED DECEMBER 31, 2018
    * Q4 LOSS PER SHARE $1.17
    * AS OF DECEMBER 31, 2018, ODONATE HAD $139.1 MILLION IN
CASH,
COMPARED TO $198.1 MILLION AS OF DECEMBER 31, 2017.
    * EXPECT TO COMPLETE ENROLLMENT IN PHASE 3 STUDY OF
TESETAXEL IN
PATIENTS WITH METASTATIC BREAST CANCER, IN H2 OF 2019
    * EXPECT TO REPORT TOP-LINE RESULTS FROM PHASE 3 STUDY OF
TESETAXEL IN PATIENTS WITH METASTATIC BREAST CANCER IN 2020

Source text for Eikon:  ID:nBw7Vc6dna 
Further company coverage:  ODT.O 

 ((Reuters.Briefs@thomsonreuters.com;;))